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BACKGROUND: Extracorporeal photopheresis (ECP)
is an immunosuppressive treatment that involves
leukocyte apheresis, psoralen and UV light treatment,
and subsequent reinfusion. Patients treated with ECP
are usually immunosuppressed. Bacterial contamination
therefore poses a much unwanted risk, but incidence
data are lacking.
PATIENTS AND METHODS: We screened all 1922
consecutive ECP procedures scheduled within a roughly
3-year period for eligibility. Those with missing data on
ECP method (inline or offline) or type of venous access
(peripheral or central) were excluded. ECPs with
complete aerobic and anaerobic microbial testing of
baseline patient blood samples (n = 1637) and of ECP
cell concentrates (n = 1814) were included in the
analysis.
RESULTS: A test for microbial contamination was
positive for 1.82% of the cell concentrates, with central
venous access was the most significant risk factor for the
contamination (odds ratio = 19). Patient blood samples
were positive in 3.85% of cases, but no patients became
septic. Staphylococcus spp. were most abundant, and
products with bacterial contamination did not cause side
effects after reinfusion. There were no significant
differences in contamination rates between inline and
offline ECP.
CONCLUSION: These findings stress the importance of
sterile procedures and the benefits of using peripheral
over central venous access for reducing the risk of
bacterial contamination in ECP.
E
xtracorporeal photopheresis (ECP) is a therapeutic
procedure consisting of leukocyte apheresis, treat-
ment of the collected cells with 8-methoxypsoralen
(8-MOP), ultraviolet A (UVA) light irradiation, that
causes covalent binding of 8-MOP with DNA, and subse-
quent reinfusion of treated product back to the patient with-
out storage.1 This therapy adds to transplantation tolerance
or in autoimmune diseases and is typically applied for
patients that are refractory to first line therapy and that are
often subject to a complex immunosuppressive regimen.2
The required medical devices are available as com-
bined equipment with apheresis and UVA irradiation in a
single machine (inline ECP), or as separate devices (offline
ECP). The latter requires that the user connects the
leukapheresis bag with the UV irradiation bag, as the former
is not UVA permeable. The components may be connected
prior to the procedure (closed ECP), or during the proce-
dure while the patient is connected (open ECP, sometimes
classified differently by regulatory authorities). Possible
combinations of these are closed inline, closed offline, and
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open offline ECP. Apart from this, both ECP types require
connections to apply 8-MOP.
To start with ECP, leukapheresis requires access to
peripheral veins or a central venous catheter (CVC). Periph-
eral venous access used to cause bacterial contamination in
1–2% of healthy blood donors until the advent of pre-
donation sampling, a preventive measure that introduced a
bag to the tubing system for the initial 15–30 mL of the
donation process.3,4 This in combination with improved
skin disinfection lowered the rate of microbial contamina-
tion to approximately 0.03%.5,6 In autologous stem cell
transplant (ASCT), on the other hand, bacterial contamina-
tion rates of up to 4.5% are still common.7,8 The affected
patients are treated under antibiotic protection, as there is
sufficient time between donation and reinfusion to obtain
diagnostic test results.9 In ECP, however, bacterial contami-
nation typically remains undetected, because the ECP prod-
uct is quickly reinfused without bacterial testing.
Undetected bacteria could, in principal, have severe conse-
quences. Up to now, data on bacterial contamination rates
in ECP are lacking. Therefore, we retrospectively collected
and analyzed data from sterility testing of ECP procedures
performed at our institution to get to know the incidence of
bacterial contamination in ECP patients and products.
PATIENTS, MATERIALS, AND METHODS
Patients
A total of 1922 ECP procedures scheduled at our hospital
from September 26, 2012 through August 31, 2015 were
screened for eligibility (Table 1). Most of the patients (79%)
had suffered graft-versus-host disease (GvHD) after autolo-
gous stem cell transplantation and received treatment on
the basis of their clinical symptoms for several weeks to sev-
eral months. Patients with other conditions like cutaneous
autoimmune diseases were usually treated for longer
periods. Treatment frequencies were adjusted to clinical
needs. Treatments that met eligibility criteria were included
in the analysis as outlined in Fig. 1.
ECP treatment protocol
Treatment was carried out as either closed inline or open off-
line ECP as described above.10 Closed inline photopheresis
can be administered with a single needle and was therefore
preferentially but not exclusively used for patients with lim-
ited venous access. Other patients received offline ECP.
Photopheresis was carried out as described previ-
ously.10 Briefly, standardized open offline ECP and closed
inline ECP procedures were used.11 Open offline ECP was
performed with the Cobe Spectra (Cobe, Terumo BCT),
Spectra Optia (Optia, Terumo BCT) or the Amicus
(Fresenius Kabi) device using acid citrate dextrose (ACD-A)
for anticoagulation. Heparin was additionally used if clotting
was observed. Patients received calcium as required. ECP
was delivered via a central or peripheral venous access
depending on the condition of the patient’s veins.
Required connections in open offline ECP were between
patient and apheresis tubing set, for sampling and 8-MOP
application, to the UV irradiation bag, and back to the patient.
Transfusion sets with 200 μm filters were used for the latter.
Closed inline ECP was performed with the Uvar XTS
(Therakos). There were no connection steps apart from
venous punctuation and sampling with 8-MOP addition.
Sterility testing
Blood samples for sterility testing were taken from the
peripheral or central venous line before the start of aphere-
sis. Samples from the cell concentrates were taken before
8-MOP addition and UV illumination at the bedside, as
closed inline ECP does not allow removal of the bag. Treat-
ments and sampling were performed in controlled environ-
ment equipped with H13 filtered ventilation. Aerobic and
anaerobic culture bottles (BD Bactec Standard Anaerobic/F
and Aerob/F, respectively) were incubated for 7 days at
30-32°C with a sample volume of 3-5 mL and 7-10 mL,
respectively. Positive cultures were isolated and differenti-
ated by matrix-assisted laser desorption ionization-time of
flight (MALDI TOF, Bruker Daltonik GmbH Life Sciences)
mass spectrometry, and antibiotic resistance testing was
performed using the BD Phoenix system.
Statistical analysis
Data was collected in Microsoft Excel 2010, and R was used to
calculate statistical significance using the Wilson score interval
with continuity correction using its built-in prop.test function.
TABLE 1. Patient characteristics
Patients* 68
Sex (male [%] / female [%]) 57,4%/42,6%









Bronchiolitis obliterans following lung
transplantation
3
Number of treatments per patient 19 (1–136)
Total number of completed treatments 1868
Closed inline ECP (Uvar XTS) 25.3%
Open offline ECP (Cobe) 71.7%
Open offline ECP (Optia) 1.9%
Open offline ECP (Amicus) 0.8%
Missing data on method 0.2%
Numbers represent median value with range in parentheses
unless otherwise indicated.
* Total number.
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RESULTS
Bacterial contamination rate
Complete information on the ECP method (online or off-
line), type of vascular access (central or peripheral), and
bacterial contamination rate (sterility testing) was available
for 1814 ECP cell concentrates. We identified a positive
microbial test results in a total of 33 ECP cell concentrates
(1.82%). Central venous access, which was required in 20%
Fig. 1. Patient recruitment and causes of drop out.
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of the ECP procedures, was more frequently associated with
bacterial contamination of ECP cell concentrates (7.38%
positive) than peripheral access (0.41% positive, Table 2,
p < 2.2 × 10−16, odds ratio 19). Patient blood samples col-
lected before the start of the procedure were available in
1637 cases. From these, 63 tested positive, with significant
differences between central and peripheral venous access
(Table 2, p = 0.0026, odds ratio 2.3).
Overall, we found 73 cases of 1637 treatments, in which
sterility testing was positive either in cell concentrates
and/or patient blood samples. The rate of overlap between
procedures with positive ECP cell concentrates and positive
patient blood sample was low (16 of 73, 22%). In an addi-
tional 10 procedures, only the cell concentrate was positive
(14%), and in another 47 instances, only the patient blood
sample was positive (64%).
Patient blood samples had a significantly higher contam-
ination rate than samples from cell concentrates (3.85% of
1637 vs. 1.82% of 1814 respectively, p = 0.00044). Contamina-
tion proportions in patients’ blood and in cell concentrates
were not equally distributed. The frequency of positive sam-
ples for patients’ blood and for cell concentrate samples was
unequally distributed (Fig. 2). Patients with fewer ECP treat-
ments tended to have more frequent unsterile findings.
Of note, we did not detect significant differences
between inline and offline ECP with regard to bacterial
detection rates in ECP cell concentrates or patient blood
samples (p = 0.068 and p = 1, respectively, Table 2). In addi-
tion, none of the bacterially contaminated products caused
adverse events upon reinfusion.
Bacterial species distribution
Samples testing positive for microbiological contamination
exhibited a large and heterogenous variety of germs. The
majority of the identified bacteria or fungus belong to the
human skin flora, mouth flora, and/or intestinal flora:
Staphylococcus epidermidis, Propionibacterium acnes,
Acinetobacter Iwoffi, Actinomyces odontolyticus, Staphylo-
coccus capitis, Micrococcus luteus, Staphylococcus aureus,
Staphylococcus hominis, Citrobacter freundii, Candida
guilliermondii, Enterobacter cloacae, Prevotella bivia,
Haemophilus parainfluenzae, Staphylococcus haemolyticus,
TABLE 2. Microbial detection rates* for (A) offline versus inline ECP and (B) peripheral versus central venous access
ECP products Patient blood
Percent positive 95% CI n Percent positive 95% CI n
(A)
Offline ECP 2.18% (1.50–3.13%) [30/1378] 3.93% (2.94–5.22%) [48/1220]
Inline ECP 0.69% (0.18–2.17%) [3/436] 3.60% (2.10–6.00%) [15/417]
(B)
Peripheral access 0.41% (0.17–0.95%) [6/1448] 3.11% (2.27–4.23%) [41/1319]
Central venous access 7.38% (5.00–10.68%) [27/366] 6.92% (4.49–10.44%) [22/318]
* Detection rates refer to different sample populations.
Fig. 2. Proportion of unsterile samples from peripheral or
central venous blood (A) or from ECP cell concentrates (B) per
patient.
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Staphyloccous simulans, Staphylococcus lugdunesis, Enterococ-
cus faecium, Klebsiella pneumoniae, and Capnocytophaga
ochracea.
In addition, some species are environmental bacteria
that can be found in soil, air, and/or water: Spores, Micro-
coccus luteus, Bacillus pumilus (resistant to UV light), Can-
dida guilliermondii, Enterobacter cloacae, and Pseudomonas
aeruginos. Interestingly, Bacillus altitudinis is a germ which
was first isolated from cryogenic tubes used for collecting
air samples from high altitudes.12
Five patient blood samples contained two different bacte-
ria (Acinetobacter Iwoffii and Staphylococcus aureus, Staphylo-
coccus aureus and Staphylococcus epidermidis, Staphylococcus
simulans and Staphylococcus epidermidis, Staphylococcus
lugdunensis and Staphylococcus capitis, Prevotella bivia and
Haemophilus parainfluenza). In one of these cases, the cell
concentrate also tested positive, but only for one bacterial spe-
cies (Prevotella bivia).
The distribution of detected bacterial species separated
by ECP system type is shown in Table 3.
DISCUSSION
In this large retrospective study, we found an overall micro-
bial contamination rate of 1.82% in the cell concentrates of
extracorporeal photopheresis. This figure is comparable to
that of apheresis procedures for the collection of other
blood components, such as platelets and hematopoietic
stem cells.
Bacterial contamination rates in platelet concentrates
from healthy donors reportedly range from 0.01 to 0.2%.13
The frequency of positive culture tests that failed in confir-
mation testing is usually higher, i.e., 0.11 to 0.72%.5,14,15
Negative confirmation testing can occur due to inappropri-
ate diagnostic techniques and may reflect contamination
with low numbers of bacteria in the inoculum or with bacte-
ria that require special growth conditions. We did not dis-
tinguish between these factors and included all positive
findings. Thus, the initial positive frequencies are techni-
cally closer to those observed in our patients.
Bacterial contamination rates in hematopoietic stem
cell apheresis range from 0.2 to 24%, averaging about 3%.16
Higher frequencies in patients may be caused by additional
handling steps during the procedure. These include disin-
fection as well as the diversion of the first milliliters after
venipuncture for predonation sampling which, however, has
been shown to substantially decrease the contamination
rate.17 The type of venous access used is another difference
between healthy blood donors and patients undergoing
apheresis. In our study, a central venous catheter (CVC)
was required in 20% of ECP procedures, and CVC use was
associated with a 19-fold higher risk for cell concentrate
contamination. Though none of the patients became obvi-
ously septic at the time of treatment, these findings illustrate
the risk of bacteremia in patients with a central venous line.
Microbial contamination risk was not evenly distributed
among the patients. We found a subgroup of patients with a
high frequency of contaminations up to a maximum of 56%
of the cell concentrates. Patients with high contamination
rates had a comparable low treatment number, e.g., because
of uncontrollable grade IV graft-versus-host disease. In addi-
tion, central venous catheter contamination contributed to
positive findings. Bacterial contamination in these patients
indicates therefore at least in part the severity of the underly-
ing disease.
Bacterial contamination may be impacted by the type of
centrifugation. Recently intermittent flow with the Amicus
(Fresenius Kabi) was shown to be disadvantageous in platelet
apheresis compared to continuous flow apheresis using the
Trima (Terumo BCT).18,19 This disfavors inline ECP that uses
intermittent flow technique. On the other hand, the buffy coat
layer of bacteria is unknown. Bacteria could distribute freely
in plasma, or they could sediment together with red blood
cells and platelets. Intermittent flow apheresis using the
Latham bowl technique as in Therakos devices, in contrast to
the technique used within the Amicus, collects less selected
TABLE 3. Bacterial species in ECP cell concentrates









Staphylococcus epidermidis – 4 13
Staphylococcus aureus – 1 13































































Staphylococcus epidermidis 3 12 11
Staphylococcus capitis – 7 5
Pseudomonas aeruginosa – 1 1

























* Data from 1814 procedures.
† Data from 1637 procedures.
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cell suspensions in general,10,20 though there are exceptions
to this.21 Inferior collection ability of inline ECP could trans-
late to a reduced bacterial enrichment. In addition, this
method processes lower blood volumes, thus further decreas-
ing the possibility of contamination in bacteremic patients.
Higher collection ability of offline ECP methods trans-
lates to successful single day treatments.22 Inline ECP, in
contrast, requires treatments on two adjacent days.
In our study, no significant differences were observed
between microbial contamination in inline and offline ECP.
Patients were not randomized and preferentially treated off-
line, if a central venous access was available. Central venous
lines, in contrast to venous canula, are handled in a sterile
way. However, this is more than outweighed by the risk
from inapparent catheter infections. The contamination risk
was thus increased in offline ECP in our study.
The difference in microbial contamination rates
between ECP cell concentrates (1.82%) and patient blood
samples (3.85%) might be explained by the fact that the lat-
ter samples were collected before apheresis and, thus, had
the same effect as predonation sampling. In addition, the
apheresis technology itself could have contributed to bacte-
rial depletion to some degree as described above.
We found 24 different bacterial species with Staphylococcus
spp. being most abundant. Most of the bacteria we detected
were part of human skin flora. These may indicate a contamina-
tion by the handling steps. However, these may also indicate
that patients for ECP with skin diseases cannot be disinfected
successfully with standard procedures. Contamination with the
same bacterial type in bag and patient supports this explanation.
The type of bacterial contamination is of relevance from
a clinical point of view, as antibiotic susceptibility depends in
part on the species. From a technical point of view, there is
no contamination that can be regarded as acceptable. There
are no commensal bacteria in cell suspensions.
Regardless of the cause of microbial contamination, it
is highly unwanted. Patients referred for ECP are usually
severely immunosuppressed like in solid organ transplanta-
tion or graft-versus-host disease. Their risk for septic com-
plications is therefore increased. On the other side, bacterial
contamination of ECP is questionable for two reasons. First,
ECP cell concentrates are not stored but reinfused immedi-
ately after UV treatment, thus eliminating the chances for
bacterial replication. Second, 8-MOP injection with subse-
quent UV light exposure acts like a pathogen inactivation
that reduces bacterial growth potential by several log
units.23 Thus, it can be assumed that any relevant bacterial
replication potential is effectively reduced in ECP treatment.
Pathogen inactivation by ECP, however, is speculative.
It is therefore mandatory to avoid contamination as much
as possible. Disinfection before venipuncture or central line
connection was done following a standardized protocol in
this study. Patients in need of ECP frequently have skin con-
ditions that are prone to bacterial infections as illustrated by
the findings of this study. Thus, effective skin disinfection
techniques such as those defined for whole blood donation
should also be used in ECP.24 In addition, the presented
data do clearly favor peripheral access for ECP, as contami-
nation by central venous access is by far the most significant
risk for bacterial contamination.
This study is the first to evaluate bacterial contamina-
tion in ECP cell suspension bags and in ECP patients. Steril-
ity sampling was scheduled for every treatment within the
study period, and all patients were considered for inclusion.
Most patients and treatments could be included, but drop-
outs could have impacted the results to some degree. Data
have also to be interpreted with caution, as patient and
treatment factors with potential impact on contamination,
such as venous access and therefore type of ECP, were cho-
sen on a clinical basis and not according to this study.
Though it is not possible to conclude on ECP types, it seems
reasonable to recognize the contamination risk for ECP in
general, especially for patients with central venous access.
The relevance of these findings is unclear, as ECP com-
prises always pathogen inactivation and cell suspensions
would not be stored. This disfavors bacterial testing. The
clinical relevance, however, is unclear, and clinical follow
up was helpful. In addition, the clinical relevance of inap-
parently contaminated catheters in these frequently immu-
nosuppressed patients calls for further studies.
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